mRNA Synthesis & Manufacturing Market Size to Hit USD 1.87 Billion by 2034

According to Nova One Advisor, the global mRNA synthesis & manufacturing market size is calculated at USD 1.58 billion in 2025 and is expected to be hit around USD 1.87 billion by 2034, growing at a compound annual growth rate (CAGR) of 1.9% over the forecast period 2025 to 2034. A study published by Nova One Advisor a sister firm of Precedence Research.

Ottawa, Nov. 13, 2025 (GLOBE NEWSWIRE) -- The global mRNA synthesis & manufacturing market size is calculated at USD 1.55 billion in 2024, grows to USD 1.58 billion in 2025, and is projected to hit around USD 1.87 billion by 2034, growing at a CAGR of 1.9% from 2025 to 2034.

mRNA Synthesis & Manufacturing Market Key Takeaways

• North America dominated the mRNA synthesis and manufacturing market with a revenue share in 2024.
• Asia Pacific is expected to grow at the fastest CAGR in the market during the forecast period.
• By type of product, the drug substance (APIs) segment dominated the market with a revenue share in 2024.
• By type of product, the drug product (FDFs) segment is expected to grow at the fastest CAGR in the market during the forecast period.
• By application area, the mRNA-based vaccines segment led the market with the largest revenue share in 2024.
• By application area, the mRNA-based therapeutics segment is expected to grow significantly in the market during the forecast period.
• By therapeutic area, the infectious diseases segment held the highest market share in 2024.
• By therapeutic area, the oncological disorders segment is expected to grow significantly in the market during the forecast period.

Download a Sample Report Here@ https://www.novaoneadvisor.com/report/sample/9216

What is mRNA Synthesis and manufacturing?

mRNA synthesis is a cell-free process known as in vitro transcription, which applies a DNA template, nucleotides, and enzymes to produce messenger RNA (mRNA) molecules. Production involves large-scale manufacturing of this synthesized mRNA, which is modified for stability and effectiveness, then expressed for therapeutic applications, such as in vaccines or other forms. The main aim is to create synthetic mRNA to train cells to produce intended proteins for healthcare therapy purposes.

The achievement of anti-COVID-19 vaccines has shaped an enormous requirement for the continuous supply of mRNA-based new vaccines. In the forecast period, many promising leads, particularly those exhibiting improved efficacy, are expected to be commercially launched. Additionally, considering the active participation of major pharma companies and new entrants, the advanced pipeline of mRNA drugs is likely to grow further, which drives the growth of the market.

What are the Key Drivers in the mRNA Synthesis and manufacturing Market?

Emerging innovation in mRNA synthesis technologies enhances the stability, bioavailability, and targeting effectiveness. Increasing cooperative efforts and partnerships speed up the scalability of production and technology adoption. Increasing funding and the incorporation of AI-based discovery platforms enhance the development pipeline, so major healthcare players have undertaken various initiatives, including consolidating mRNA-driven product portfolios, entering into strategic deals, and creating significant economic investments, which drive the market growth.

What are the Ongoing Trends in the mRNA Synthesis and Manufacturing Market?

• In October 2025, WHO and MPP launched phase 2.0 of the mRNA technology transfer programme. Phase 2.0 of the mRNA technology transfer programme marks a defining moment in the global pursuit of equitable access to vaccines and regional manufacturing sovereignty.
• In May 2025, TriLink BioTechnologies, a Maravai LifeSciences company, is fueling the future of mRNA research, starting with a significant donation to top academic labs across the U.S. and Europe. The donation commemorates the launch of TriLink’s first mRNA synthesis kit featuring CleanCap capping technology, an all-in-one kit with TriLink's innovative products in one box at a competitive price.

Immediate Delivery Available | Buy This Premium Research (Global Deep Dive USD 3800) https://www.novaoneadvisor.com/report/checkout/9216

Report Scope of mRNA Synthesis and Manufacturing Market

Report Attribute	Details
Market size value in 2025	USD 1.58 Billion
Revenue forecast in 2034	USD 1.87 Billion
Growth rate	CAGR of 1.9% from 2025 to 2034
Base year for estimation	2024
Historical data	2018 - 2024
Forecast period	2025 - 2034
Quantitative units	Revenue in USD million/billion, and CAGR from 2025 to 2034
Segments covered	Type of Product, Application Area, Therapeutic Area
Regional scope	North America; Europe; Asia Pacific; Latin America; MEA
Country scope	U.S.; Canada; Mexico; UK; Germany; France; Italy; Spain; Denmark; Sweden; Norway; India; China; Japan; Australia; South Korea; Thailand; Brazil; Argentina; Saudi Arabia; UAE; South Africa; Kuwait
Key companies profiled	F. Hoffmann-La Roche Ltd., Jena Bioscience GmbH, Merck KGaA KGaA, Yeasen Biotechnology (Shanghai) Co., Ltd., BOC Sciences, Thermo Fisher Scientific , Inc., Maravai LifeSciences, New England Biolabs, Creative Biogene, HONGENE.

For more information, visit the Nova One Advisor website or email the team at sales@novaoneadvisor.com | Call us : +1 804 420 9370

Research & Discovery Stage

Generate early mRNA constructs to validate biological activity, target protein expression, and delivery approach.

1.2 Key Reagents

Category	Examples	Purpose
Template DNA	Plasmid DNA (pDNA), linearized DNA	Encodes mRNA sequence
Enzymes	T7 RNA polymerase, DNase I	Catalyze transcription, remove DNA
Nucleotides	ATP, CTP, GTP, modified UTP (e.g., N1-methyl-pseudoUTP)	Building blocks; modifications reduce immunogenicity
Capping reagents	ARCA cap analogs, CleanCap	Provides 5′ mRNA cap
Buffers	Transcription buffer, RNase-free buffers	Maintain reaction stability
Purification resins	Silica columns, magnetic beads	Remove impurities

Segmental Insights

By Product Analysis

Which Product Led the MRNA synthesis and manufacturing market in 2024?

The drug substance segment accounted for the dominating share of the market in 2024, as mRNA drugs have a limited production cycle and are not limited to short peptide sequences. mRNA drugs have huge advantages of high therapeutic effectiveness, low medicine toxicity, and high specificity, and presently massive potential in the therapies of metabolic diseases, cancer, genetic diseases, and the prevention of infectious diseases

Whereas the drug product (FDFs) segment is predicted to register rapid expansion in the forecasting period, as this type of product is produced in cell-free systems by an enzymatic process that is simply scaled up to produce huge quantities in a limited time, often affordable than complex protein-based therapeutics that need to cell culture facilities.

By application area Analysis

How did the mRNA-based vaccines segment dominate the market in 2024?

In 2024, the mRNA-based vaccines segment captured the biggest share of the mRNA synthesis and manufacturing market, as mRNA vaccines are considered a significant substitute to traditional conventional vaccines due to their massive potency, efficacy, and safety. It has a huge success rate in preventing severe hospitalization, illness, and death. mRNA vaccines show a hopeful alternative to conventional vaccine strategies because of their high capacity for rapid development and potential for low-cost manufacture and safe and effective administration.

Although the mRNA-based therapeutics segment will expand fastest during 2025-2034, as mRNA-based therapeutics experience rapid advancement and production capability. mRNA-driven therapy is used for many diseases that are resistant to present therapies, such as infectious diseases, cancer, metabolic genetic diseases, CVD, cerebrovascular diseases, and others.

By Therapeutic Area Analysis

How did the infectious diseases dominate the Market in 2024?

The infectious diseases segment held the biggest share of the mRNA synthesis and manufacturing market in 2024, as mRNA-based vaccines applicable for infectious diseases avoid infection by stimulating the body to produce particular immune responses by mRNA molecules that encode pathogenic proteins. As compared to outdated vaccines such as inactivated, subunit, live attenuated, recombinant protein, and viral vectors, mRNA vaccines provide numerous benefits, including potent efficacy, high safety, scalable large-scale manufacturing, and affordability.

Although the oncological disorders segment will expand fastest during 2025-2034, as mRNAs are extensively used for cancer immunotherapy in various forms of therapeutic modalities, with cancer vaccines, targeted T-cell therapies, satisfying antibodies, and immunomodulatory proteins. This technology provides comprehensive care for cancer patients.

By Regional Analysis

Why did North America Dominate the Market in 2024?

North America dominates the mRNA synthesis and manufacturing market due to high expenditure on R&D, an advanced healthcare system, and regulatory support for advanced genetic research. Increasing applications of mRNA-driven therapeutics in tissue engineering, regenerative medicine, and healthcare testing, along with an increasing demand for organ transplantation, all these factors drive the growth of the market.

How did the Asia Pacific Grow Notably in the Market in 2024?

The Asia Pacific region is the fastest growing in the mRNA synthesis and manufacturing market, with extensive spending, increasing R&D, cost-effectiveness, and regulatory support, specifically in China and India. Major factors include increasing healthcare technology adoption, a big and growing market for vaccines and therapeutics, and the advancement of particular infrastructure for these developed technologies. India and China are major growth hubs due to their cost-effective production and supportive government environments, which drive the growth of the market.

Top Companies in the mRNA Synthesis & Manufacturing Market

• F. Hoffmann-La Roche Ltd.
• Jena Bioscience GmbH
• Merck KGaA  KGaA
• Yeasen Biotechnology (Shanghai) Co., Ltd.
• BOC Sciences
• Thermo Fisher Scientific, Inc.
• Maravai LifeSciences
• New England Biolabs
• Creative Biogene
• HONGENE.

What are the Recent Developments in the MRNA synthesis and manufacturing market?

• In February 2025, Scientists in Paris are set to advance novel technology that could streamline the production of mRNA-based vaccines while also improving global access to the technology. CEPI is providing US$4.7 million to DNA Script to advance its capability to automate the manufacture of synthetic DNA templates—the starting blueprint required to produce mRNA.
• In November 2025, Innovent Biologics, Inc., jointly announced with Sanegene Bio USA Inc. (SanegeneBio), a global clinical-stage biotechnology company focused on developing best-in-class RNAi medicines for obesity, cardiometabolic, and autoimmune diseases, that the preliminary results from the first-in-human (FIH) Phase 1 clinical study of IBI3016, an experimental small interfering RNA (siRNA) medicine targeting angiotensinogen mRNA
• In November 2025, QIAGEN announced it had entered into a definitive agreement to fully acquire Parse Biosciences, a leading provider of scalable, instrument-free solutions for single-cell research.
  

More Insights in Nova One Advisor:

• mRNA Vaccines for Animals Market- The global mRNA vaccines for animals market size was estimated at USD 81.65 million in 2024 and is expected to reach USD 9,734.19 million in 2034, expanding at a CAGR of 61.3% during the forecast period of 2025 and 2034.
• U.S. mRNA Synthesis Raw Materials Market - The U.S. mRNA synthesis raw materials market size was exhibited at USD 867.45 million in 2024 and is projected to hit around USD 1,161.26 million by 2034, growing at a CAGR of 2.96% during the forecast period 2025 to 2034.
• Personalized Cancer Vaccine Market - The Personalized cancer vaccine market size was exhibited at USD 208.66 million in 2024 and is projected to hit around USD 8,502.05 million by 2034, growing at a CAGR of 44.88% during the forecast period 2025 to 2034.
• Cell Reprogramming Market - The Cell Reprogramming Market size was exhibited at USD 406.65 million in 2024 and is projected to hit around USD 925.38 million by 2034, growing at a CAGR of 8.57% during the forecast period 2025 to 2034.
• mRNA Synthesis Raw Materials Market - The global mRNA Synthesis Raw Materials market size was valued at USD 2.45 billion in 2023 and is projected to surpass around USD 3.25 billion by 2033, registering a CAGR of 2.87% over the forecast period of 2024 to 2033.
• U.S. mRNA Therapeutics Market - The U.S mRNA Therapeutics market size was estimated at USD 5.10 billion in 2023 and is expected to be worth around USD 12.18 billion by 2033, poised to grow at a compound annual growth rate (CAGR) of 9.1% during the forecast period 2024 to 2033.
• mRNA Therapeutics Contract Development & Manufacturing Organization Market - The mRNA therapeutics contract development & manufacturing organization market size was exhibited at USD 4.85 billion in 2024 and is projected to hit around USD 14.14 billion by 2034, growing at a CAGR of 11.29% during the forecast period 2025 to 2034.
• Vaccine Market - The vaccine market size was exhibited at USD 80.45 billion in 2024 and is projected to hit around USD 140.72 billion by 2034, growing at a CAGR of 5.75% during the forecast period 2025 to 2034.
• mRNA Therapeutics Market - The global mRNA therapeutics market size was valued at USD 12.19 billion in 2023 and is projected to surpass around USD 58.90 billion by 2033, registering a CAGR of 17.06% over the forecast period of 2024 to 2033. 
• Digital Pathology Market - The digital pathology market size was exhibited at USD 1.11 billion in 2024 and is projected to hit around USD 2.43 billion by 2034, growing at a CAGR of 8.1% during the forecast period 2025 to 2034.
• Optical Imaging Market - The global optical imaging market size is calculated at USD 2326.33 million in 2024, grow to USD 2579.9 million in 2025, and is projected to reach around USD 6546.17 million by 2034, registering a CAGR of 10.9% from 2025 to 2034.
• Embolization Particles Market - The global embolization particles market size is calculated at USD 1.15 billion in 2024, grows to USD 1.29 billion in 2025, and is projected to reach around USD 3.65 billion by 2034, accelerating at a CAGR of 12.23% from 2025 to 2034.
• mHealth Market - The global mHealth market size is calculated at USD 71.25 billion in 2024, grow to USD 81.44 billion in 2025, and is projected to reach around USD 271.17 billion by 2034, to grow at a CAGR of 14.3% from 2025 to 2034.
• Medical Implant Market - The global medical implant market size is calculated at USD 121.15 billion in 2024, grows to USD 130.11 billion in 2025, and is projected to reach around USD 247.38 billion by 2034, growing at a CAGR of 7.4% from 2025 to 2034.
• Intravenous (IV) Ibuprofen Market - The global Intravenous (IV) ibuprofen market size is calculated at USD 8.89 million in 2024, grow to USD 10.10 million in 2025, and is projected to reach around USD 31.83 million by 2034, registering a CAGR of 13.6% from 2025 to 2034.
  

Segments Covered in the Report

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2034. For this study, Nova one advisor, Inc. has segmented the mRNA synthesis & manufacturing market.

Type of Product 

• Drug Substance (APIs)
• Drug Product (FDFs)

Application Area 

• mRNA-based Vaccines
• mRNA-based Therapeutics

Therapeutic Area 

• Infectious Diseases
• Oncological Disorders
• Other Diseases
  

By Regional

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa (MEA)
  

Immediate Delivery Available | Buy This Premium Research Report (Global Deep Dive USD 3800) https://www.novaoneadvisor.com/report/checkout/9216

About-Us

Nova One Advisor is a global leader in market intelligence and strategic consulting, committed to delivering deep, data-driven insights that power innovation and transformation across industries. With a sharp focus on the evolving landscape of life sciences, we specialize in navigating the complexities of cell and gene therapy, drug development, and the oncology market, enabling our clients to lead in some of the most revolutionary and high-impact areas of healthcare.

Our expertise spans the entire biotech and pharmaceutical value chain, empowering startups, global enterprises, investors, and research institutions that are pioneering the next generation of therapies in regenerative medicine, oncology, and precision medicine.

Our Trusted Data Partners

Towards Chemical and Materials | Precedence Research | Statifacts | Towards Packaging | Towards Healthcare | Towards Food and Beverages | Towards Automotive | Towards Consumer Goods | Nova One Advisor | Nutraceuticals Func Foods | Onco Quant | Sustainability Quant | Specialty Chemicals Analytics   | Towards Chem and Material

Web: https://www.novaoneadvisor.com/

Contact Us

USA: +1 804 420 9370

Email: sales@novaoneadvisor.com

For Latest Update Follow Us: LinkedIn